Coty Establishes First Scientific Advisory Board for Skincare Innovation

Coty Inc. has launched its first scientific advisory board.

The board unites scientific experts from diverse technical disciplines, selected for their unique expertise and contribution to cutting-edge research, according to the company.

The board will convene twice annually to inform and inspire innovations within Coty’s R&D specialists, thereby fortifying the company’s efforts to shape the future of skincare.

The first meeting, held at Coty’s Skincare Research & Innovation Center of Excellence in Monaco, united these leading scientists to discuss the current themes in skin health and skin repair. The experts provided valuable insights and feedback that will continue to shape Coty’s R&D initiatives and product innovation strategies across all its skincare brands.

“This year marks our 120th anniversary as pioneers in the beauty industry, and I’m honored that such acclaimed scientific minds have agreed to come together to help define the future of Coty skincare as part of our Scientific Advisory Board. Each member has been carefully selected because they are at the forefront of their respective disciplines,” said Sue Nabi, CEO of Coty. “Their ongoing insights will play a pivotal role as we continue to collaborate and drive skincare innovation forward for the benefit of all our consumers.”

Members of Coty’s Scientific Advisory Board are the following:

Dr. Miriam Merad

Dr. Miriam Merad is a director of precision at the Immunology Institute in New York. Medrad worked at the Icahn School of Medicine at Mount Sinai for over two decades as a professor of medicine. She received her doctor of philosophy, phD, immunology, at Stanford University School of Medicine in 2001.

Dr. Emma Guttman

Dr. Emma Guttman is a professor of dermatology and immunology in New York. Emma Guttman-Yassky is the Waldman professor of dermatology and immunology and health system chair of the department of dermatology at the Icahn School of Medicine at Mount Sinai in New York City. She is the director of the occupational dermatitis clinic and director of the laboratory for inflammatory skin diseases. Dr. Guttman earned her MD from Sackler School of Medicine at the Tel-Aviv University, and a PhD from the Bar-Ilan University, Israel. After obtaining her Israeli Board certification in dermatology at Rambam Medical Center/Technion, Israel, Dr. Guttman moved to the US to pursue a two-year postdoctoral fellowship at The Rockefeller University in the Laboratory for Investigative Dermatology. Upon completion of her fellowship, she became board-certified by the American Board of dermatology after a second dermatology residency training at the Weill-Cornell Medical College, in New York. Dr. Guttman’s major clinical and research focus areas are atopic dermatitis (AD)/eczema and alopecia areata. Her research made paradigm-shifting discoveries on the immunologic basis of atopic dermatitis (AD)/eczema in adults and children with atopic dermatitis, enriching the understanding of the pathophysiology of this common disorder, opening the door and accelerating testing of novel immune, pathway-specific drugs in this disease. She is now testing (both clinically and mechanistically) multiple targeted therapeutics for atopic dermatitis that target Th2, Th22, and Th17/IL-23 axis. Recently, Dr. Guttman extended her research interest to hair loss disorders such as alopecia areata and scarring hair loss disorders, chronic hand eczema, keloids, ichtyosis, and other skin diseases, in which her findings are reportedly translated to novel therapeutic targets. Dr. Guttman is considered one of the world’s leading experts in inflammatory skin diseases. Her achievements have been repeatedly highlighted by the media including the New York Times, ABC News, CBS News, Daily News, Reuters, Wall Street Journal, NY1 and others.

Dr. Patrick Bui

Dr. Bui is head of department of the reconstructive and aesthetic Ppastic surgery unit, Craniofacial Surgery at the American Hospitalmember of the Academy of Surgery. He is also an educator at Paris V University Scientific Director of the University Diploma and a judicial expert at the Paris Court of Appeal.

Pr. Selim Aractingi

Dr. Aractingi is a team leader, cutaneous biology labs, Cochin Institute in Paris. He reportedly highly rated in seven conditions. His top areas of expertise are melanoma, giant congenital melanocytic nevus, psoriasis and actinic keratosis. His clinical research consists of co-authoring 144 peer reviewed articles in the past 15 years.

Pr. Wei Liu

Beijing-based dermatologist Dr Liu’s research focuses on the following topics: application of operations research techniques in radiotherapy; robustness quantification in proton therapy; accurate and fast dose linear energy transfer calculation in proton therapy; motion management; patient outcomes study via machine learning and big data; and application of artificial intelligence in radiotherapy. Dr. Liu pursues the application of large language models such as ChatGPT in radiotherapy. His research integrates interdisciplinary methods from physics, operations research, computer science and radiation oncology. Focus areas include: robust biological optimization and robustness quantification; dose-averaged linear energy transfer calculation; motion management; patient outcomes studies; artificial intelligence; large language models; and significance to patient care. Dr. Liu’s research develops novel algorithms for proton therapy that achieve robustness quantification and robust optimization. His research can advance tumor control through more reliable target coverage, causing less toxicity to nearby critical organs. His research in this area helps improve patients’ quality of life and survival. It also advances proton therapy to achieve the long-term goals of improving the therapeutic ratio of proton therapy for patients with cancer. Dr. Liu’s professional highlights include associate section editor, International Journal of Radiation OncologyBiologyPhysics; John Laughlin Young Scientist Award recipient, American Association of Physicists in Medicine, 2019; and an honoree with the new scientific terminology, “Liu-Limit,” University of Texas MD Anderson Cancer Center, 2012.

Pr. Deng Xingwang

Deng Xingwang, a professor of life science in Beijing, was a Daniel C. Eaton professor at Yale University. He received his Ph.D in University of California, Berkeley in 1989 and started his research group in Yale University in 1992 as an assistant professor. He was promoted associate professor in 1995, and full professor in 2001. His work has been reported in around 300 peer-reviewed publications, 14 in “Nature,” “Science” and “Cell” journals. Deng was awarded The Kumho Science International Award in 2003 and was elected as member of US National Academy of Sciences in 2013. His research interests are focused on light-mediated development in plants.

Dr. Jaci Santana

Dr. Santana graduated from the Federal University of Pernambuco with a degree in medicine in 1991. She specializes in dermatology at the Hospital das Clínicas da UFPE. She is a specialist in dermatology from the Brazilian Society of Dermatology and a specialist in Hansenology from the Brazilian Society of Hansenology.